Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.

There is no fulltext present in this item.

Title:	Attenuation of invariant natural killer T-cell anergy induction through intradermal delivery of alpha-galactosylceramide.
Author(s):	Bontkes, H.J.; Moreno, M.; Hangalapura, B.N.; Lindenberg, J.J.; Groot, J. de; Lougheed, S.; Vliet, H.J. van der; Eertwegh, A.J. van den; Gruijl, T.D. de; Blomberg, B.M.E. von; Scheper, R.J.
Publication year:	2010
Source:	Clinical Immunology, vol. 136, iss. 3, (2010), pp. 364-374
ISSN:	1521-6616
DOI:	https://doi.org/10.1016/j.clim.2010.04.019
Annotation:	1 september 2010
Publication type:	Article / Letter to editor
Please use this identifier to cite or link to this item : http://hdl.handle.net/2066/88407
Display more details
Subject:	NCMLS 2: Immune Regulation ONCOL 3: Translational research
Organization:	Laboratory of Hematology
Journal title:	Clinical Immunology
Volume:	vol. 136
Issue:	iss. 3
Page start:	p. 364
Page end:	p. 374
Abstract:	CD1d restricted, alpha-galactosylceramide (alphaGC) responsive invariant (i)NKT cells positively regulate immune responses. Both intravenous and intradermal administered alphaGC are known to activate iNKT cells. iNKT cells become unresponsive to a second intravenous alphaGC injection, whereas no data are available regarding potential anergy upon intradermal administration. Here, comparative analysis of two intradermal versus two intravenous injections in mice demonstrated that iNKT cell anergy was prevented by intradermal injection and when combined with a vaccine, superior tumor protection afforded by intradermally administered alphaGC. Moreover, human skin dendritic cells (DC) took up intradermally injected alphaGC and activated iNKT cells upon migration, while iNKT cells in human skin-draining lymph nodes expanded in response to alphaGC presented either by exogenously added DC or by CD1d positive antigen presenting cells in the lymph nodes. In conclusion, glycolipids such as alphaGC may greatly improve the efficacy of skin immunization strategies, targeting cutaneous and lymph node DC.